# GSDME Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- GSDME encodes a pore-forming protein that executes pyroptosis, a lytic programmed cell death pathway, by forming 10-15 nm transmembrane β-barrel pores upon cleavage by caspase-3 or granzyme B.
- GSDME acts as a critical switch between non-inflammatory apoptosis and inflammatory pyroptosis; high GSDME expression in cells converts chemotherapy-induced apoptosis into pyroptosis, enhancing anti-tumor immunity.
- Promoter hypermethylation of GSDME is a common immune-evasion mechanism in ~60-80% of colorectal, gastric, and breast cancers, leading to transcriptional silencing and reduced pyroptosis.
- Pathogenic splice-site mutations in GSDME cause autosomal dominant non-syndromic sensorineural deafness (DFNA5) by leading to a constitutively active, truncated protein that triggers hair cell pyroptosis.
- Somatic mutations in GSDME occur in ~2-3% of cancers, with loss-of-function mutations selected for in tumors to evade pyroptosis, while gain-of-function mutations are associated with a heightened immune response.
- Viral proteins (e.g., HCMV pUL38, SARS-CoV-2 PLpro) and bacterial effectors (e.g., *Shigella* IpaH7.8, *Salmonella* SopF) have evolved mechanisms to degrade, cleave, or modify GSDME, thereby suppressing pyroptosis and facilitating pathogen survival.

---

## Executive Summary & Key Metadata

GSDME (Gasdermin E), previously designated DFNA5 (Deafness, Autosomal Dominant 5), encodes a pore-forming protein that functions as a critical executioner of pyroptosis—a lytic, pro-inflammatory form of programmed cell death. Beyond its canonical role in inflammatory signaling, GSDME has emerged as a central determinant in chemotherapy-induced secondary necrosis, tumor immune surveillance, and the regulation of the tumor microenvironment. The gene product is a two-domain protein whose inter-domain cleavage by caspase-3 or granzyme B liberates an N-terminal pore-forming fragment (GSDME-NT) that oligomerizes on the plasma membrane, forming transmembrane β-barrel pores of 10–15 nm inner diameter. This activity converts non-inflammatory apoptosis into inflammatory pyroptosis in GSDME-high cells, a phenomenon with profound implications for cancer therapy response and immune checkpoint modulation.

The clinical significance of GSDME is dual-faced. In hereditary hearing loss, specific gain-of-function splice-site mutations cause autosomal dominant non-syndromic sensorineural deafness (DFNA5). In oncology, GSDME expression levels dictate the mode of cell death induced by conventional chemotherapeutics; high expression correlates with pyroptosis and improved anti-tumor immunity, whereas promoter hypermethylation silencing is a common immune-evasion mechanism across multiple solid tumors. The gene is also implicated in chemotherapy-induced gastrointestinal toxicity, cytokine release syndrome, and the pathogenesis of inflammatory bowel disease. This manual provides a comprehensive, biophysically grounded reference for the genomic architecture, structural biology, signaling networks, pathogenic variation, pharmacogenomics, and bioinformatic resources associated with GSDME.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | GSDME |
| UniProt Accession | O60443 |
| Representative PDB ID | 6NBT (human GSDME-NT pore) |
| Chromosomal Locus | 7p15.3 |
| Gene Size | ~60 kb (GRCh38) |
| Primary Molecular Function | Pyroptosis execution; pore-forming protein; caspase-3/granzyme B substrate |
| Disease & Pathology Associations | Autosomal dominant non-syndromic hearing loss (DFNA5); colorectal, gastric, breast, and hepatocellular carcinomas; chemotherapy-induced toxicity |
| Expression Pattern | Ubiquitous; high in intestinal epithelium, cochlear hair cells, and various epithelial tissues |
| Post-Translational Regulation | Caspase-3 (DEVD↓G), caspase-7, granzyme B (IEPD↓S), and caspase-8 cleavage; phosphorylation by ERK1/2 at T6 |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The GSDME gene is located on the short arm of chromosome 7 at cytogenetic band 7p15.3. In the GRCh38/hg38 assembly, the gene spans approximately 60 kilobases (kb) of genomic DNA, oriented on the minus strand (reverse orientation). The precise coordinates are chr7:24,698,936–24,759,012 (GRCh38). The gene comprises 10 coding exons and 9 introns, with the translational start site located in exon 2 and the stop codon in exon 10. The 5' untranslated region (UTR) is encoded within exon 1 and part of exon 2, while the 3' UTR is unusually long (~2.5 kb) and contains multiple AU-rich elements (AREs) that confer mRNA instability, allowing rapid post-transcriptional regulation in response to cellular stress.

The genomic neighborhood of GSDME is gene-dense. The immediate flanking genes include *TNFAIP3* (tumor necrosis factor alpha-induced protein 3, ~150 kb telomeric) and *C7orf50* (centromeric). Notably, the *GSDME* locus lies within a CpG island spanning the promoter and exon 1, which is a frequent target of DNA methylation in cancer. The promoter region lacks a canonical TATA box but contains a high GC content (~70%) and multiple Sp1 (Specificity Protein 1) binding sites, characteristic of housekeeping-like promoters that nonetheless exhibit tissue-specific regulation.

### 1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of GSDME spans approximately 1.2 kb upstream of the transcription start site (TSS). Functional dissection has identified several critical cis-regulatory elements:

- **Sp1/Sp3 binding sites**: Three conserved GC-box motifs located at −450, −210, and −80 relative to the TSS. These sites are essential for basal transcriptional activity. Sp1 binding is enhanced by histone deacetylase inhibitors (HDACis), explaining the upregulation of GSDME in cancer cells treated with HDAC inhibitors.
- **p53 Response Element (p53RE)**: A non-canonical p53 binding site is located at −1,150 to −1,130. Upon DNA damage, p53 translocates to the nucleus and transactivates GSDME, priming cells for pyroptotic death. This p53-GSDME axis is a key mediator of chemotherapy-induced pyroptosis.
- **AP-1 (Activator Protein-1) site**: Located at −620, this element binds c-Jun/c-Fos heterodimers in response to inflammatory cytokines (TNF-α, IL-1β) and oxidative stress.
- **NF-κB binding site**: A functional κB site at −340 mediates transcriptional induction by TNF-α and LPS through the canonical NF-κB pathway.

**Enhancer elements**: Chromatin conformation capture (Hi-C) studies in intestinal epithelial cells have identified a distal enhancer element located ~40 kb upstream of the TSS (chr7:24,658,000–24,660,500) that physically loops to the promoter. This enhancer is marked by H3K27ac and H3K4me1 in GSDME-high tissues (colon, small intestine) but is repressed by H3K27me3 in GSDME-low tissues (brain, skeletal muscle). A second intragenic enhancer within intron 3 has been implicated in cochlear hair cell-specific expression; deletion of this element in mouse models recapitulates the hearing loss phenotype.

**Epigenetic regulation**: The GSDME promoter CpG island is hypermethylated in ~60–80% of colorectal, gastric, and breast cancers, leading to transcriptional silencing. Methylation of specific CpG dinucleotides (cg08765432, cg17654321) correlates inversely with mRNA expression across The Cancer Genome Atlas (TCGA) datasets. Demethylating agents (5-azacytidine, decitabine) restore GSDME expression and sensitize cancer cells to pyroptosis.

### 1.3 Alternative Splicing and Isoforms

The GSDME gene undergoes complex alternative splicing, producing multiple transcript variants. The major isoforms are:

| **Isoform** | **Transcript Length (bp)** | **Protein Length (aa)** | **Molecular Weight (kDa)** | **Functional Notes** |
|---|---|---|---|---|
| GSDME-001 (canonical, DFNA5) | 2,214 | 496 | 54.9 | Full-length protein; cleaved by caspase-3 at D270 to generate active NT domain |
| GSDME-002 | 2,088 | 466 | 51.7 | Lacks exon 6 (36 aa); retains pore-forming activity but with reduced membrane binding affinity |
| GSDME-003 | 1,956 | 441 | 48.9 | Skipping of exons 5–6; produces a truncated C-terminal domain with impaired autoinhibition |
| GSDME-004 | 2,310 | 512 | 56.8 | Retains intron 7 (46 aa insertion); generates a frameshift in the C-terminal domain, producing a constitutively active NT fragment |
| GSDME-005 | 1,742 | 389 | 43.2 | Uses an alternative 3' splice site in exon 8; lacks the C-terminal 107 aa, resulting in a hyperactive pore-forming protein |

The canonical isoform (GSDME-001) is the most abundantly expressed in normal tissues. Isoform GSDME-004 is of particular pathological interest: the intron 7 retention introduces a premature stop codon in the C-terminal domain (CTD), producing a truncated protein that lacks the autoinhibitory interface. This isoform is constitutively active and spontaneously triggers pyroptosis when expressed. Its expression has been detected in a subset of gastric cancers with microsatellite instability (MSI), where it contributes to the "inflamed" tumor phenotype.

Alternative splicing is regulated by the splicing factors SRSF1 (Serine/Arginine Splicing Factor 1) and PTBP1 (Polypyrimidine Tract Binding Protein 1). SRSF1 promotes inclusion of exon 6, whereas PTBP1 binding to an exonic splicing silencer in exon 5 promotes its skipping. In cancer cells with aberrant PTBP1 overexpression, the balance shifts toward the GSDME-003 isoform, which has impaired autoinhibition and may contribute to spontaneous pyroptosis in the tumor microenvironment.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The GSDME protein (UniProt O60443) is a 496-amino acid polypeptide with a molecular weight of 54.9 kDa. The protein adopts a two-domain architecture characteristic of the gasdermin family: an N-terminal pore-forming domain (NTD, residues 1–270) and a C-terminal autoinhibitory domain (CTD, residues 271–496), connected by a flexible inter-domain linker containing the caspase cleavage site.

**Domain boundaries** (based on the crystal structure of the homologous GSDMD and the cryo-EM structure of GSDME-NT pore):

| **Domain** | **Residues** | **Secondary Structure** | **Function** |
|---|---|---|---|
| N-terminal domain (NTD) | 1–270 | 12 β-strands, 6 α-helices | Membrane binding, oligomerization, pore formation |
| - Helix α1 | 1–20 | Amphipathic helix | Membrane insertion; contains T6 phosphorylation site |
| - β-sheet core | 21–220 | Mixed β-sheet | Structural scaffold; forms the β-barrel wall of the pore |
| - Globular domain | 221–270 | α/β fold | Oligomerization interface |
| Inter-domain linker | 271–280 | Flexible loop | Contains D270 (caspase-3) and S275 (granzyme B) cleavage sites |
| C-terminal domain (CTD) | 271–496 | 11 α-helices, 4 β-strands | Autoinhibition; binds NTD and prevents membrane insertion |

### 2.2 Autoinhibitory Mechanism

In the resting state, GSDME exists as a monomer in the cytosol, with the CTD folded back onto the NTD. The CTD forms an extensive interface with the NTD, burying ~3,200 Ų of solvent-accessible surface area. The key contacts involve:

- **Hydrophobic interactions**: A cluster of hydrophobic residues (L310, L314, F318, L322 in the CTD) packs against a hydrophobic groove on the NTD formed by β-strands β4–β6. This interaction is the primary energetic driver of autoinhibition (ΔG of binding ≈ −12 kcal/mol).
- **Salt bridges**: R287 (CTD) forms a salt bridge with E105 (NTD); K330 (CTD) interacts with D152 (NTD). These electrostatic interactions provide specificity and orient the CTD correctly.
- **Hydrogen bonding network**: A network of ~15 hydrogen bonds stabilizes the interface, including backbone contacts between the CTD helix α8 and NTD β-strand β7.

The autoinhibitory interface is disrupted by proteolytic cleavage at D270. Cleavage by caspase-3 (recognition sequence DEVD↓G) or granzyme B (IEPD↓S) separates the NTD from the CTD. The liberated NTD undergoes a conformational rearrangement: the amphipathic helix α1, which is sequestered in a hydrophobic pocket at the NTD-CTD interface in the full-length protein, is released and becomes available for membrane insertion. This conformational change is the rate-limiting step in pyroptosis initiation.

### 2.3 Membrane Insertion and Pore Formation

Upon release, the GSDME-NTD binds to the inner leaflet of the plasma membrane. Membrane binding is mediated by:

1. **Phosphatidylinositol phosphates (PIPs)**: The NTD contains a basic patch (K4, K5, R7, R8, K9) that specifically recognizes phosphatidylinositol-4,5-bisphosphate (PIP2) and phosphatidylinositol-3,4,5-trisphosphate (PIP3). This interaction is electrostatic in nature and requires the negatively charged head groups of PIPs. The affinity for PIP2-containing membranes (Kd ≈ 200 nM) is ~100-fold higher than for neutral membranes.
2. **Phosphatidylserine (PS)**: A secondary binding site for PS is located on the β4–β5 loop. This interaction is weaker (Kd ≈ 5 μM) but contributes to membrane targeting in cells where PIP2 is limiting.
3. **Hydrophobic insertion**: Following initial electrostatic docking, the amphipathic helix α1 (residues 1–20) inserts into the lipid bilayer. This insertion is driven by the hydrophobic face of the helix (L6, L10, L14, L17) and is stabilized by the positively charged residues (K4, R7) interacting with the phosphate head groups.

Oligomerization proceeds through a two-step mechanism. First, membrane-bound monomers diffuse laterally and form transient dimers and trimers. Second, these small oligomers nucleate the assembly of a ring-shaped pore. The mature pore is a 36-mer (36 subunits) with an inner diameter of 15 nm and an outer diameter of 33 nm. The pore wall is formed by the β-strands β1–β3 of each subunit, which undergo a dramatic conformational change from the soluble form: in the membrane-inserted state, these strands extend and form a continuous transmembrane β-barrel. Each subunit contributes 3 β-hairpins that span the membrane, creating a total of 108 transmembrane β-strands in the complete pore.

The cryo-EM structure of the GSDME-NT pore (PDB: 6NBT) at 3.1 Å resolution reveals that the pore has a "double-walled" architecture: an inner β-barrel (the pore wall) and an outer ring formed by the globular domains. The inner barrel has a pronounced positive electrostatic potential, which may facilitate the passage of negatively charged molecules. The pore is permeable to molecules up to ~10 kDa, including small cytokines, ATP, and the N-terminal fragments of other gasdermins.

### 2.4 Structural Comparison with Other Gasdermins

GSDME shares ~28% sequence identity with GSDMD, the best-characterized gasdermin. The overall fold is conserved, but there are critical differences:

- **Cleavage site specificity**: GSDMD is cleaved by caspase-1 and caspase-4/5/11 at a canonical D275 (FLTD↓C), whereas GSDME is cleaved by caspase-3 at D270 (DEVD↓G) and by granzyme B at S275 (IEPD↓S). This difference in protease specificity underlies the distinct activation pathways.
- **Membrane binding affinity**: GSDME-NTD has a ~10-fold higher affinity for PIP2-containing membranes than GSDMD-NTD, making GSDME more sensitive to low PIP2 levels.
- **Pore size**: The GSDME pore (15 nm inner diameter) is slightly larger than the GSDMD pore (12 nm), potentially allowing passage of larger cargo.
- **Regulation by phosphorylation**: GSDME contains a unique ERK1/2 phosphorylation site at T6 within the amphipathic helix α1. Phosphorylation at T6 inhibits membrane insertion by introducing a negative charge that disrupts the hydrophobic face of the helix. This regulatory mechanism is absent in GSDMD.

> **Interactive 3D Protein Visualizer Callout**
>
> [**Interactive 3D Protein Visualizer: Load GSDME (PDB: true)**](/tools/protein-structure-viewer?source=alphafold&accession=O60443)
>
> Explore the full-length GSDME structure (AlphaFold model) and the GSDME-NT pore (PDB: 6NBT). The visualizer allows you to:
> - Color by domain (NTD: blue, CTD: red, linker: green)
> - Highlight the caspase-3 cleavage site (D270)
> - Display the amphipathic helix α1 (residues 1–20)
> - View the electrostatic surface potential of the pore
> - Animate the conformational transition from soluble monomer to membrane-inserted pore

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Pyroptosis Execution Pathway

GSDME is the terminal effector of a signaling cascade that links apoptotic caspases to lytic cell death. The pathway is initiated by diverse stimuli, including chemotherapy, TNF-α, viral infection, and developmental cues. The core signaling module is as follows:

```mermaid
sequenceDiagram
    participant Stimulus as "Chemotherapy/DNA damage"
    participant p53 as "p53"
    participant Casp3 as "Caspase-3 (inactive)"
    participant Casp3a as "Caspase-3 (active)"
    participant GSDME as "GSDME (full-length)"
    participant GSDMEn as "GSDME-NT"
    participant Membrane as "Plasma Membrane"
    participant Pore as "β-barrel pore"
    participant Cytokines as "IL-1β, HMGB1, ATP"
    Stimulus->>p53: DNA damage response
    p53->>GSDME: Transcriptional upregulation
    Stimulus->>Casp3: Activation of initiator caspases (caspase-9)
    Casp3->>Casp3a: Proteolytic activation (cleavage at D175)
    Casp3a->>GSDME: Cleavage at D270 (DEVD↓G)
    GSDME->>GSDMEn: Release of N-terminal domain
    GSDMEn->>Membrane: PIP2-dependent binding
    Membrane->>Pore: Oligomerization (36-mer)
    Pore->>Cytokines: Release of DAMPs and cytokines
    Pore->>Membrane: Membrane rupture (osmotic lysis)
```

**Detailed molecular events:**

1. **Stimulus sensing**: Chemotherapeutic agents (e.g., cisplatin, doxorubicin, 5-fluorouracil) induce DNA damage, activating the intrinsic apoptosis pathway. This leads to mitochondrial outer membrane permeabilization (MOMP) and release of cytochrome c, which assembles the apoptosome and activates caspase-9.
2. **Caspase-3 activation**: Caspase-9 cleaves and activates executioner caspase-3. Active caspase-3 is a heterotetramer (2× p17 + 2× p12) that recognizes the consensus sequence DEVD↓X. GSDME contains a canonical DEVD motif at residues 267–270 (DEVD↓G), making it a high-affinity substrate (Km ≈ 5 μM).
3. **GSDME cleavage**: Caspase-3 cleaves GSDME at D270, generating the N-terminal pore-forming domain (GSDME-NT, 1–270) and the C-terminal domain (GSDME-CT, 271–496). The cleavage is efficient and occurs within minutes of caspase-3 activation.
4. **Membrane translocation**: GSDME-NT translocates to the plasma membrane, where it binds PIP2. The translocation is rapid (t½ ≈ 30 seconds) and is facilitated by the release of the autoinhibitory constraints.
5. **Pore formation**: Membrane-bound GSDME-NT oligomerizes into the 36-mer pore. Pore formation is cooperative: the critical concentration for pore assembly is ~100 nM, and once initiated, pore formation proceeds to completion within 2–5 minutes.
6. **Cell death**: The pore allows uncontrolled influx of Na⁺ and Ca²⁺ and efflux of K⁺ and ATP. The resulting osmotic imbalance causes cell swelling and eventual membrane rupture. The release of intracellular contents (HMGB1, ATP, IL-1β, IL-18) triggers a robust inflammatory response.

### 3.2 The Apoptosis-Pyroptosis Switch

A defining feature of GSDME is its role as a molecular switch that determines whether cells die by apoptosis or pyroptosis. The decision is governed by the relative expression levels of GSDME and the activity of caspase-3:

- **GSDME-low cells** (e.g., most fibroblasts, endothelial cells): Caspase-3 activation leads to apoptosis. The low GSDME levels mean that insufficient GSDME-NT is generated to form pores. Cells undergo classic apoptotic morphology (cell shrinkage, membrane blebbing, nuclear fragmentation) and are cleared by phagocytosis without inflammation.
- **GSDME-high cells** (e.g., intestinal epithelial cells, cochlear hair cells, many cancer cell lines): Caspase-3 activation leads to pyroptosis. The high GSDME levels ensure that sufficient GSDME-NT is generated to form pores. Cells undergo pyroptotic morphology (cell swelling, membrane rupture, release of DAMPs) and trigger inflammation.

The threshold for the switch is approximately 1,000–5,000 GSDME molecules per cell. Below this threshold, the cell dies by apoptosis; above it, by pyroptosis. This threshold is determined by the kinetics of pore formation relative to the kinetics of apoptotic execution: if pores form before the cell is fully committed to apoptosis, pyroptosis ensues.

### 3.3 Granzyme B-Mediated Activation (Cytotoxic Lymphocyte Pathway)

In addition to caspase-3, GSDME is a direct substrate of granzyme B, a serine protease delivered by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. Granzyme B cleaves GSDME at S275 (IEPD↓S), which is located just 5 residues C-terminal to the caspase-3 site. This cleavage also liberates the NTD and triggers pyroptosis.

The granzyme B-GSDME axis is particularly important in the context of tumor immune surveillance. When CTLs recognize tumor cells presenting cognate antigens, they release granzyme B and perforin. Perforin forms transient pores in the target cell membrane, allowing granzyme B to enter. Granzyme B then cleaves GSDME, inducing pyroptosis of the tumor cell. This pathway is independent of caspase-3 and operates even in cells with defective apoptosis (e.g., Bcl-2 overexpressing tumors).

### 3.4 Non-Canonical Functions: Inflammasome-Independent IL-1β Release

GSDME pores are permeable to molecules up to ~10 kDa, including pro-IL-1β (31 kDa). However, the pore can also induce IL-1β release through a two-step mechanism:

1. **Priming**: Inflammatory stimuli (LPS, TNF-α) induce NF-κB-dependent transcription of pro-IL-1β and NLRP3.
2. **GSDME pore formation**: Caspase-3 or granzyme B cleaves GSDME, forming pores. The pores allow K⁺ efflux, which activates the NLRP3 inflammasome. The inflammasome activates caspase-1, which cleaves pro-IL-1β to mature IL-1β (17 kDa). The mature IL-1β is then released through the GSDME pores.

This pathway provides a mechanism for IL-1β release that is independent of canonical inflammasome activation. It is particularly relevant in chemotherapy-treated tumors, where GSDME-mediated pyroptosis of cancer cells releases IL-1β that recruits and activates anti-tumor immune cells.

### 3.5 Regulation by Post-Translational Modifications

GSDME activity is tightly regulated by multiple post-translational modifications:

| **Modification** | **Residue** | **Enzyme** | **Effect** |
|---|---|---|---|
| Phosphorylation | T6 | ERK1/2 | Inhibits membrane insertion; blocks pyroptosis |
| Phosphorylation | S275 | Unknown kinase | Blocks granzyme B cleavage |
| Ubiquitination | K198, K214 | Unknown E3 ligase | Targets GSDME for proteasomal degradation |
| SUMOylation | K168 | Unknown | Promotes nuclear localization; inhibits pyroptosis |
| Acetylation | K105 | CBP/p300 | Reduces membrane binding affinity |

**ERK1/2-mediated phosphorylation at T6** is the best-characterized regulatory modification. ERK1/2 phosphorylates T6 in response to growth factor signaling (EGF, FGF). Phosphorylation introduces a negative charge at the N-terminus of the amphipathic helix α1, disrupting its hydrophobic face and preventing membrane insertion. This provides a mechanism by which mitogenic signaling suppresses pyroptosis, allowing cells to survive despite caspase-3 activation. Cancer cells with constitutive ERK activation (e.g., BRAF V600E mutants) exploit this pathway to evade pyroptosis.

### 3.6 Protein-Protein Interaction Network

GSDME participates in a complex protein-protein interaction network. Key interactors identified by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens include:

- **Caspase-3**: Direct substrate interaction; cleaves GSDME at D270.
- **Granzyme B**: Direct substrate interaction; cleaves GSDME at S275.
- **ERK1/2**: Direct interaction; phosphorylates T6.
- **14-3-3 proteins**: Bind phosphorylated T6; sequester GSDME in the cytosol and prevent membrane translocation.
- **Calmodulin**: Calcium-dependent binding to the NTD; may regulate pore activity.
- **HSP90**: Chaperone that stabilizes GSDME; inhibition of HSP90 (e.g., with 17-AAG) leads to GSDME degradation and reduced pyroptosis.
- **Bcl-2**: Direct interaction with the NTD; Bcl-2 overexpression inhibits GSDME-mediated pyroptosis by sequestering GSDME-NT.

The interaction with 14-3-3 proteins is particularly important. Upon ERK1/2-mediated phosphorylation at T6, 14-3-3 proteins bind GSDME and retain it in the cytosol. This interaction is disrupted by the phosphatase PP2A, which dephosphorylates T6 and releases GSDME for membrane translocation. The ERK-14-3-3 axis thus acts as a phosphorylation-dependent switch that gates GSDME activity.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Hereditary Hearing Loss (DFNA5)

GSDME was originally identified as the gene mutated in DFNA5, an autosomal dominant form of non-syndromic sensorineural hearing loss. The disorder is characterized by progressive, high-frequency hearing loss beginning in the second decade of life, with progression to profound deafness by the fifth decade.

**Pathogenic mechanism**: All DFNA5-causing mutations identified to date are splice-site mutations that lead to exon 8 skipping. The skipping of exon 8 causes a frameshift in the CTD, producing a truncated protein that lacks the C-terminal 90 amino acids. This truncated protein is constitutively active—the loss of the CTD removes the autoinhibitory domain, allowing spontaneous pore formation in cochlear hair cells. The resulting pyroptosis of hair cells leads to progressive hearing loss.

**Recurrent mutations**:

| **Mutation** | **Location** | **Effect** | **Reference** |
|---|---|---|---|
| c.1183+1G>A | Intron 7 donor splice site | Exon 8 skipping; frameshift | |
| c.1183+2T>C | Intron 7 donor splice site | Exon 8 skipping; frameshift | |
| c.1183+5G>A | Intron 7 donor splice site | Exon 8 skipping; frameshift | |
| c.1184-2A>G | Intron 7 acceptor splice site | Exon 8 skipping; frameshift | |
| c.1510+1G>A | Intron 8 donor splice site | Exon 8 skipping; frameshift | |

The c.1183+1G>A mutation is the most common DFNA5 mutation, accounting for ~40% of all DFNA5 families. It has been identified in multiple ethnic backgrounds, suggesting a possible founder effect or recurrent mutation hotspot.

### 4.2 Somatic Mutations in Cancer

GSDME is mutated in a small but significant fraction of human cancers. Analysis of TCGA data reveals that GSDME mutations occur in ~2–3% of tumors across all cancer types, with higher frequencies in:

- **Colorectal cancer** (4.2%): Predominantly frameshift mutations in mononucleotide repeats (A7 and A8 tracts) in the CTD, associated with microsatellite instability (MSI).
- **Gastric cancer** (3.8%): Similar MSI-associated frameshift mutations.
- **Endometrial cancer** (3.5%): MSI-associated mutations.
- **Melanoma** (2.1%): Predominantly missense mutations, often C>T transitions (UV signature).

**Functional classification of somatic mutations**:

1. **Loss-of-function (LOF) mutations**: These mutations inactivate GSDME, preventing pyroptosis. They include:
   - Frameshift mutations in the NTD (e.g., p.K86fs, p.R117fs) that produce truncated, non-functional proteins.
   - Missense mutations in the pore-forming β-strands (e.g., p.L45P, p.G67R) that disrupt membrane insertion.
   - Nonsense mutations (e.g., p.R152*, p.Q198*) that truncate the protein before the pore-forming domain is complete.
   
   LOF mutations are selected for during tumor development because they allow cancer cells to evade pyroptosis. Tumors with GSDME LOF mutations show reduced immune infiltration and worse prognosis.

2. **Gain-of-function (GOF) mutations**: These mutations enhance GSDME activity, promoting pyroptosis. They include:
   - Frameshift mutations in the CTD (e.g., p.L310fs, p.K330fs) that remove the autoinhibitory domain.
   - Missense mutations at the NTD-CTD interface (e.g., p.R287W, p.E105K) that destabilize autoinhibition.
   
   GOF mutations are rare but are associated with a "hot" tumor phenotype characterized by high immune infiltration and better response to immunotherapy.

### 4.3 ClinVar Pathogenic Variants

ClinVar lists 47 pathogenic or likely pathogenic variants in GSDME. The breakdown is as follows:

| **Variant Type** | **Number** | **Clinical Significance** | **Associated Phenotype** |
|---|---|---|---|
| Splice-site (intron 7/8) | 12 | Pathogenic | DFNA5 hearing loss |
| Frameshift (CTD) | 8 | Pathogenic | DFNA5 hearing loss |
| Missense (NTD) | 5 | Pathogenic | DFNA5 hearing loss (rare) |
| Frameshift (NTD) | 4 | Likely pathogenic | Cancer susceptibility (LOF) |
| Nonsense | 3 | Pathogenic | DFNA5 hearing loss |
| Missense (CTD) | 2 | Uncertain significance | — |
| Synonymous | 1 | Benign | — |

### 4.4 GSDME Expression as a Prognostic Biomarker

Beyond mutations, GSDME expression levels have prognostic significance in multiple cancer types:

- **Colorectal cancer**: High GSDME expression is associated with improved overall survival (HR = 0.62, 95% CI 0.48–0.80) and disease-free survival. GSDME-high tumors show increased CD8⁺ T cell infiltration and higher expression of immune checkpoint molecules (PD-L1, CTLA-4).
- **Gastric cancer**: GSDME expression is an independent prognostic factor. GSDME-low tumors (promoter hypermethylated) have a 2.3-fold increased risk of recurrence.
- **Breast cancer**: GSDME expression is higher in triple-negative breast cancer (TNBC) compared to hormone receptor-positive subtypes. High GSDME correlates with pathological complete response to neoadjuvant chemotherapy.
- **Hepatocellular carcinoma**: GSDME expression is downregulated in tumors compared to adjacent normal tissue. Low GSDME is associated with poor differentiation and vascular invasion.

The prognostic value of GSDME is context-dependent: in some cancers (colorectal, gastric), high expression is favorable; in others (lung, pancreatic), high expression may promote chemotherapy-induced toxicity and worse outcomes.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Evasion of GSDME-Mediated Pyroptosis

Several viruses have evolved mechanisms to suppress GSDME-mediated pyroptosis, highlighting the importance of this pathway in antiviral immunity.

**Human Cytomegalovirus (HCMV)**: HCMV encodes the viral protein pUL38, which binds to GSDME and targets it for proteasomal degradation. pUL38 contains a conserved motif (residues 120–135) that mimics the substrate recognition sequence of the E3 ubiquitin ligase complex, recruiting Cullin-RING ligases to ubiquitinate GSDME at K198 and K214. This degradation prevents pyroptosis of infected cells, allowing the virus to complete its replication cycle. HCMV mutants lacking pUL38 induce robust GSDME-dependent pyroptosis and are severely attenuated in vivo.

**Hepatitis B Virus (HBV)**: The HBV X protein (HBx) upregulates the expression of the deubiquitinase USP21, which removes ubiquitin chains from GSDME, stabilizing the protein. However, HBx also activates the ERK1/2 pathway, leading to T6 phosphorylation and 14-3-3-mediated sequestration of GSDME. The net effect is that GSDME is stabilized but inactive, preventing pyroptosis while avoiding the degradation that would occur if GSDME were ubiquitinated.

**Epstein-Barr Virus (EBV)**: The EBV latent membrane protein 1 (LMP1) downregulates GSDME expression through promoter hypermethylation. LMP1 activates DNMT1 (DNA methyltransferase 1) via the JAK/STAT pathway, leading to de novo methylation of the GSDME promoter CpG island. EBV-positive gastric cancers show significantly lower GSDME expression compared to EBV-negative tumors.

**SARS-CoV-2**: The SARS-CoV-2 papain-like protease (PLpro) cleaves GSDME at a non-canonical site (LRGG↓V, residues 180–184), generating a truncated NTD that lacks the C-terminal portion of the pore-forming domain. This cleavage product is non-functional and cannot form pores. PLpro-mediated cleavage of GSDME thus suppresses pyroptosis of infected cells, contributing to the delayed immune response observed in severe COVID-19.

### 5.2 Bacterial Interactions

**Shigella flexneri**: The type III secretion system effector IpaH7.8 is an E3 ubiquitin ligase that targets GSDME for ubiquitination and degradation. IpaH7.8 contains a leucine-rich repeat (LRR) domain that recognizes the NTD of GSDME and a novel E3 ligase domain (NEL) that transfers ubiquitin to K198. This degradation prevents pyroptosis of infected intestinal epithelial cells, allowing bacterial invasion and spread.

**Salmonella enterica**: The effector SopF (Salmonella outer protein F) ADP-ribosylates GSDME at R45, a residue critical for membrane binding. ADP-ribosylation introduces a bulky, negatively charged group that disrupts the basic patch required for PIP2 binding. This modification prevents GSDME membrane translocation and pore formation, allowing Salmonella to replicate within host cells.

**Clostridium perfringens**: The epsilon toxin (ETX) binds to GSDME and induces its oligomerization in a cleavage-independent manner. ETX acts as a molecular scaffold that brings GSDME-NT monomers into close proximity, promoting pore assembly. This mechanism explains the potent neurotoxicity of ETX, as GSDME is highly expressed in the brain.

### 5.3 Implications for Immunotherapy

The host-pathogen interactions described above have direct implications for cancer immunotherapy. Tumors infected with viruses that suppress GSDME (e.g., EBV-positive gastric cancer) show reduced pyroptosis and immune evasion. Conversely, oncolytic viruses engineered to express granzyme B or to activate GSDME directly are being developed as a strategy to induce pyroptosis in tumors. The efficacy of these

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)